Why compare them?
Both are represented in Weight management, Type 2 diabetes, and Cardiovascular outcomes research, making their overlapping mechanisms and evidence maturity useful to compare.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Semaglutide vs. Liraglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceDirect comparison available
STEP 8 compared once-weekly semaglutide 2.4 mg with once-daily liraglutide 3.0 mg for 68 weeks in adults with obesity or overweight without diabetes. It does not compare diabetes products, cardiovascular outcomes, kidney outcomes, MASH, every approved dose, or individual suitability.
✓ Shared
Shared Similarities
- Both records include GLP-1R.
- Both have been studied in Weight management, Type 2 diabetes, and Cardiovascular outcomes.
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence; Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record.
? Unknown
Biggest Unknown
The biggest remaining question is how far the direct findings extend beyond the study's specific population, doses, endpoints, and duration.
Key Takeaways
Semaglutide is distinguished in the current record by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence. Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceComparable
Semaglutide: Mature human evidence. Liraglutide: Mature human evidence.
Regulatory historyComparable
Semaglutide: FDA approved for defined product-specific indications. Liraglutide: FDA approved for defined product-specific indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonAvailable
A direct study answers a defined question in a specific population, at specific doses, and over a specific duration.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Semaglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Chronic kidney disease
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Receptor activityEvidence, not a winner
SemaglutideGLP-1R
Single GLP-1 receptor agonist.
LiraglutideGLP-1R
Single GLP-1 receptor agonist.
Direct obesity comparisonEvidence, not a winner
Semaglutide−15.8% at 68 weeks
STEP 8 once-weekly semaglutide 2.4 mg arm.
Liraglutide−6.4% at 68 weeks
STEP 8 once-daily liraglutide 3.0 mg arm.
Administration formatsEvidence, not a winner
SemaglutideWeekly injection + daily tablets
Several named products have distinct routes, strengths, and instructions.
LiraglutideDaily injection
Current approved U.S. products are ready-to-use subcutaneous solutions.
Cardiovascular evidenceEvidence, not a winner
SemaglutideSELECT + diabetes programs
Product-specific evidence includes adults with established cardiovascular disease and obesity without diabetes.
LiraglutideLEADER
Defined adults with type 2 diabetes and high cardiovascular risk.
Other evidence areasEvidence, not a winner
SemaglutideKidney + MASH labels
Current product-specific U.S. labels include defined kidney and MASH indications.
LiraglutidePrediabetes, OSA, NASH research
Controlled studies exist, but these are not separate U.S. liraglutide indications.
Combination boundaryEvidence, not a winner
SemaglutideDirect GLP-1R overlap
Current labels advise against use with another GLP-1 receptor agonist or semaglutide-containing product.
LiraglutideDirect GLP-1R overlap
Current labels advise against coadministration with another GLP-1 receptor agonist or liraglutide-containing product.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Direct comparison available
- The direct comparison applies only to its defined population, doses, endpoints, and duration.
- It does not answer every regulatory, long-term, formulation, route, or individual-use question.
- A direct result should not be generalized into an objectively “better” compound.
Pathway boundary: Both activate GLP-1R. Combining them would create direct receptor and drug-class overlap; current labels advise against coadministration with another GLP-1 receptor agonist or another product containing the same active ingredient.
Current unknowns
Questions the evidence cannot answer yet
- Long-term comparative outcomes across newer products and doses, rare events at population scale, and evidence outside studied populations or approved products.
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
Community Intelligence
Emerging patterns, clearly separated from evidence
Semaglutide
No community experiences yetBe the first account holder to contribute.
Liraglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.